CNR1 and metabolic dysfunction-associated steatotic liver disease: Accordingly, increased levels of hepatic CB1R expression constitute both a consequence, but also a cause, of NAFLD and NASH development, and therefore, specifically targeting both peripheral and hepatic CB1R could constitute a promising therapeutic strategy to target NAFLD (Figure 1).